Efficacy of a text messaging (SMS) based intervention for adults with hypertension: protocol for the StAR (SMS Text-message Adherence suppoRt trial) randomised controlled trial by Bobrow, Kirsty et al.
Bobrow et al. BMC Public Health 2014, 14:28
http://www.biomedcentral.com/1471-2458/14/28STUDY PROTOCOL Open AccessEfficacy of a text messaging (SMS) based
intervention for adults with hypertension: protocol
for the StAR (SMS Text-message Adherence
suppoRt trial) randomised controlled trial
Kirsty Bobrow1,2,3*, Thomas Brennan1, David Springer1, Naomi S Levitt3, Brian Rayner4, Mosedi Namane5,
Ly-Mee Yu2, Lionel Tarassenko1 and Andrew Farmer2Abstract
Background: Interventions to support people with hypertension in attending clinics and taking their medication
have potential to improve outcomes, but delivery on a wide scale and at low cost is challenging. Some trials
evaluating clinical interventions using short message service (SMS) text-messaging systems have shown important
outcomes, although evidence is limited. We have developed a novel SMS system integrated with clinical care for
use by people with hypertension in a low-resource setting. We aim to test the efficacy of the system in improving
blood pressure control and treatment adherence compared to usual care.
Methods/design: The SMS Text-message Adherence suppoRt trial (StAR) is a pragmatic individually randomised
three-arm parallel group trial in adults treated for hypertension at a single primary care centre in Cape Town, South
Africa. The intervention is a structured programme of clinic appointment, medication pick-up reminders, medication
adherence support and hypertension-related education delivered remotely using an automated system with either
informational or interactive SMS text-messages. Usual care is supplemented by infrequent non-hypertension related
SMS text-messages. Participants are 1:1:1 individually randomised, to usual care or to one of the two active interventions
using minimisation to dynamically adjust for gender, age, baseline systolic blood pressure, years with hypertension, and
previous clinic attendance. The primary outcome is the change in mean systolic blood pressure at 12-month follow-up
from baseline measured with research staff blinded to trial allocation. Secondary outcomes include the proportion of
patients with 80% or more of days medication available, proportion of participants achieving a systolic blood pressure
less than 140 mmHg and a diastolic blood pressure less than 90 mmHg, hospital admissions, health status, retention in
clinical care, satisfaction with treatment and care, and patient related quality of life. Anonymised demographic data are
collected on non-participants.
Discussion: The StAR trial uses a novel, low cost system based on widely available mobile phone technology to deliver
the SMS-based intervention, manage communication with patients, and measure clinically relevant outcomes. The
results will inform implementation and wider use of mobile phone based interventions for health care delivery in a
low-resource setting.
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Globally, high blood pressure is the leading single risk
factor for cardiovascular and related diseases [1,2].
Individual patient-level data have shown that usual
blood pressure is “strongly and directly” associated with
cardiovascular and overall mortality risk [3], and that
lowering blood pressure reduces this risk [4-6]. Con-
trolling blood pressure at a population level may be
associated with a decrease in cardiovascular disease
regardless of the increasing burden of obesity and
diabetes [7]. The burden of disease associated with
hypertension is greatest in low-resource settings [2,8],
where there is a need for better control of blood
pressure [9,10].
Treatment to lower blood pressure includes drug
and non-drug measures as well as modification of
known life-style associated risk factors, such as smok-
ing and alcohol intake [6,11,12]. Long-term blood
pressure control requires integrating medication tak-
ing into daily life to support adherence and persisting
with treatment.
A wide range of different strategies and interventions
has been used to support patients in adhering to treat-
ment plans, although results are not consistent [13].
One strategy that may facilitate such support is the in-
tegration of a patient’s mobile (or cellular) phone in the
process of health care delivery. Globally, the mobile
phone has become the preferred tool for communication
and access to information bringing together communi-
cation and computing technology. Mobile-phone-based
interventions could address individual-level factors in
health by facilitating timely patient access to relevant
health information and support, making patient-provider
communication easier, and providing context-specific
support and prompts to action [14].
Despite widespread interest in the potential for mobile
phone based interventions to deliver disease manage-
ment and health-related behaviour change sustainably
and at scale, published evidence of effectiveness is
limited [15]. SMS-text messages are available on all
mobile phone platforms and with all providers. Text
messages have the potential to provide information
alone (informational) or provide two-way communi-
cation (interactive or bi-directional). Some but not all
trials suggest that SMS text-message reminders may
improve clinic attendance, retention in care, and self-
reported medication adherence [15]. Two trials in Spain
with short follow-up periods have explored the efficacy
of SMS-based interventions for people with hyper-
tension to improve treatment compliance and blood
pressure control. Although the trials results suggest po-
tential for small to moderate effect sizes in improved
compliance and blood pressure control, the effects were
not statistically significant [16].Methods
Design and hypothesis
The SMS Text-message Adherence suppoRt trial (StAR)
is a twelve-month, pragmatic three-arm parallel group
trial. Participants are individually randomised to one of
two trial intervention groups or an enhanced usual care
group (control) in a 1:1:1 allocation ratio (Figure 1).
We therefore plan to test whether a structured inter-
vention delivered by an automated system of SMS text-
messages providing clinic appointment and medication
pick-up reminders, medication adherence support and
hypertension-related education delivered remotely through
informational or interactive SMS text-messages is more ef-
fective than usual care in controlling blood pressure.
Setting
Participants are recruited from the Vanguard Community
Health Centre, a public sector, large primary care clinic in
Bonteheuwel, Cape Town, South Africa, serving two diverse
low-middle income communities, Langa and Bonteheuwel.
The health centre provides a full range of primary care
services with approximately 28,000 people attending each
month. The “chronic diseases of lifestyle clinic” services a
caseload of about 500 patients per week. Patients with
hypertension are managed by nurse practitioners and
doctors in structured clinics. The local Department of
Health provides medications for the treatment of hyperten-
sion in line with national and international hypertension
management guidelines [17]. Medications are provided
either pre-packed from an off-site pharmacy, or dispensed
on-site. Medications are usually provided for 28 days.
Patients are required to attend the clinic monthly to
collect their medication. There is no fee for receiving
care or medication in primary care.
Participants
Trial eligibility criteria are: (i) a clinical diagnosis of hyper-
tension and either currently receiving blood pressure
lowering medication or are about to start such medication,
(ii) a systolic blood pressure <220 mmHg and a diastolic
blood pressure <120 mmHg at enrolment (iii) aged 21
years or older, (iv) own or have daily access to a cell-
phone, (v) able to send a SMS text-message, or can do
so with help of a relative, (vi) do not live in a household
where another member has been recruited into the
trial, (vii) not pregnant or within three months post-
partum by self-report, (viii) currently residing in the
trial area and expecting to be resident for the duration
of the trial and (ix) willing to give informed consent to
take part in the trial. Patients with a systolic blood pres-
sure >175 mmHg or a diastolic blood pressure >105 mmHg
are eligible only if they have no symptoms suggesting a
hypertensive emergency and they have been evaluated
by a medical officer.
Figure 1 CONSORT diagram for SMS-text Adherence suppoRt Trial (StAR).
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The two active interventions are delivered by an auto-
mated system of SMS text-messages providing clinic ap-
pointment and medication pick-up reminders, medication
adherence support and hypertension-related education
delivered remotely using either informational or inter-
active SMS text-message.
Intervention development
We iteratively designed, developed, and tested the inter-
ventions using a formal process to synthesise existing
evidence, the opinion of clinical staff, and patients with
chronic diseases (Figure 2). [18,19]As part of this process
we developed a bank of SMS-text messages which we
mapped on a taxonomy of behaviour change techniques.
[20] Most of the content focused on the techniques of
goals and planning, repetition and substitution, social
support, and natural consequences (Table 1). The SMS
text-messages used in the intervention were developed,
translated, and tested in English, Afrikaans and isiXhosa,
the three languages most commonly spoken by people
living in Cape Town.Informational (unidirectional) SMS text-message system
Participants allocated to the informational SMS text-mes-
sage group receive an intervention that includes reminders
about medication collection, scheduled clinic appoint-
ments and follow-up text-messages (including reminders
when medicines are not collected), and a SMS-text pro-
moting specific adherence-related behaviours. The SMS-
texts are sent weekly at a time and in a language selected
by the participant. Some of the texts are personalised (in-
clude first or chosen name). The intervention is compliant
with South African regulations and ethics, and regulatory
guidelines on good SMS-practice [21].
Interactive (bidirectional SMS text-message reminders)
In addition to the intervention provided to participants
allocated to the informational SMS text-message group,
participants in the interactive SMS text-message group
can also respond to texts and send messages to the
clinic. For example, when appointment reminders are
sent to participants in the interactive SMS text-message
group, they will include an option to reply if they cannot
make their scheduled appointment and to cancel or
Figure 2 Process of intervention development adapted from Smith et al. [18].
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type of SMS text-messages sent to participants allocated
to the two intervention arms are shown in Table 2.
Usual care
Participants allocated to the usual care group only re-
ceive the SMS-texts sent to all trial participants. TheseTable 1 Examples of trial text messages mapped to behaviou
Goals & planning A pill box can help you to remember wh
For more info ask PHARMACY.
Make taking your pills part of your daily r
remember to take them regularly.
Repetition & substitution Pls remember your next CLUB DATE is on
Thnx for picking up your meds. Keeping
We missed you @ CLUB. We hope you’re
Social support Ask someone you trust to help you reme
You’re doing very well. Pls keep on with
Natural consequences Pls remember your high blood can’t be c
clinic dates, exercise&eat healthy food.messages are sent no more frequently than one SMS
text-message every four weeks. The messages are a wel-
come SMS text-message, a text confirming enrolment,
an SMS text-message on a birthday, and other SMS text-
messages about participation in the trial. Examples of the
types of SMS texts-messages sent to all trial participants
can be seen in Table 3.ral change taxonomy
en to take you high blood pills. We encourage you to get one.
outine, like when you brush your teeth. Doing this can help you
[DAY][DD/MM/YY] at [TIME].
on your pills & attending on your correct dates helps us serve you better.
OK. Pls be sure to come in to collect your MEDICINE.
mber to take your medicine as directed.
your pills, come on your clinic dates, exercise&eat healthy food.
ured. To keep healthy pls keep on with your pills, come on your
Table 2 Examples of intervention group SMS-text messages in English
• Appointment reminder SMS-texts Hi [insert name]. Pls remember your next MEDICINE DATE is on [DAY][DD/MM/YY] at [TIME].
Thnx Dr [NAME] (DR@VAN)
• In response to missing a
scheduled appointment
We missed you @ PHARMACY. We hope you’re OK. Pls be sure to come in to collect your MEDICINE.
Thnx Dr [NAME] (DR@VAN)
• Messages related to specific issues A pill box can help you to remember when to take your high blood pills. Ask at PHARMACY where
you can buy one. Thnx Dr[NAME](PHARM@VAN)
Pls be sure to take all your medicine as directed even if you feel well. Thnx Sr [NAME](SR@VAN)
Pls tell us(DR&PHARMACY)if you think your high blood pills are making you feel unwell. Ask us
about common side effects of your pills. Thnx Dr [NAME](DR&PHARM@VAN)
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between-group contamination
Clinic staff and trial participants are told that the trial
procedures involve collecting information about the num-
ber, timing, and content of text-messages for health
and thus not everyone will be receiving the exact same
number or type of messages. Participants are asked not
to share the SMS text-messages with others. SMS text-
message content is stored remotely in a message bank
on a secure server. An automated delivery system is used
to send SMS text-messages and to manage interaction
with trial participants at no cost to participants (Table 4).
The server and delivery system are managed by techni-
cians with no direct contact with trial participants. Trial
staff are clearly identifiable and distinct from clinic staff. A
trial log is kept to record and describe any unscheduled
contact between trial participants and the trial team.
Outcomes
Primary outcome measures
The primary clinical outcome is change in mean systolic
blood pressure from baseline to twelve months measured
with a validated electronic device (IEM Stabil-o-graph©)
using a standard protocol [22]. We record six sequential
blood pressure readings at 3-minute intervals. Data from
the IEM Stabil-o-graph© are uploaded to trial database
and the reported blood pressure is calculated by discard-
ing the initial reading and calculating the mean from the
five remaining readings. [23]
Secondary outcomes
Treatment adherence is assessed by calculating the
proportion of days of medication covered from rou-
tinely collected prescribing and dispensing data obtainedTable 3 Examples of trial-specific group-text messages in Eng
• Welcome SMS-text message Welcome to StAR* than
We will never ask for p
• Trial specific SMS-texts Pls remember your par
(its free) if you need to
Pls remember participa
Thnx Dr [NAME] (StAR@
• Birthday SMS-text Hi [NAME]. Happy birthduring the 12-month follow-up period [24]. Data will be
reported in three-monthly intervals. Adherence will be re-
ported as the proportion of patients with ≥80% of days
covered with medication [25], and as a continuous
measure.
Additional secondary outcomes are: proportion of par-
ticipants achieving a systolic blood pressure less than
140 mmHg and a diastolic blood pressure less than
90 mmHg, and health status measured with the EuroQol
5-Dimension and Visual Analogue Scale measures [26],
proportion of scheduled clinic appointments attended,
retention in clinical care, satisfaction with clinic services
and care using 12 five-point Likert-scale items adapted
from locally appropriate questionnaires developed to
capture patient satisfaction with services for HIV-care,
[27,28] hospital admissions, a Visual Analogue Scale for
self-reported adherence to medication, and an adapted
four-point scale evaluating basic hypertension know-
ledge. [29] We are also collecting data on the number
and type of medication changes made during the trial
and reported side-effects of medication. Anonymised
demographic data are collected on non-participants.
Trial procedures
The trial specific procedures to recruit, enrol and
follow-up participants are integrated within existing
health care delivery pathways. Participants continue to
receive clinical care from their usual care providers.
Baseline data collection
Participants are recruited from patients attending any of
the chronic disease services at the health centre. Poten-
tial participants are given information (verbal and writ-
ten) about the trial and, if willing, screened for eligibility.lish
k you for participating. The trial cell is 0XXXXXX120 (save on phone).
ersonal or banking details. Dr[NAME](StAR*@VAN)
ticipation in StAR* is voluntary. Call, text, or send plz cal 0XXXXXX372
withdraw. Thnx Dr [NAME] (StAR*@VAN)
ting in StAR is free. We do not charge you for the SMS-texts we send to you.
VAN)
day, have a great day. Thnx [NAMES](Health Team & StAR*@VAN)
Table 4 Practical aspects of sending and receiving SMS text messages
SMS text message • Receiving SMS text messages or phone calls is free in South Africa
• SMS text messages can be sent to participants through any of the local mobile phone network providers
“Please Call Me” (PCM) • PCM messages are equivalent to a missed-call and are freely available (a minimum of five PCMs are available daily)
across all local networks
Devices or credit • Participants are not be provided with mobile phones or network airtime credit
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Afrikaans. The trial screening protocol includes the stan-
dardised measurement of height, weight, waist circum-
ference, and blood pressure using a validated electronic
device and the data are entered into the patient’s clinic
record. Eligible individuals interested in participating
have the opportunity of asking trained research staff
further questions about the trial and sufficient time to
consider whether or not they wish to participate.
Consenting participants attend a baseline consultation
of 20 minutes with a trained research assistant. After
obtaining written confirmation of informed consent and
detailed contact information including the participant’s
mobile-phone number, the data are uploaded and the
system sends a “Welcome” SMS-text message to the par-
ticipant, allowing further discussion of the SMS-based
support that will be available in the trial. Participants
select the language, and the day and time of the SMS-
messages they will receive. No further specific training
is given in how to access or interpret the message. Con-
firmed receipt of the SMS-text (either in real-time or within
72 hours of registration) is a required for completion of the
enrolment procedure and trial randomisation. The research
assistant then administers a short baseline questionnaire;
details of current clinical management and medication
are extracted from paper-based and electronic records
from the clinic and other Department of Health service
providers.
Follow up to 12 months
Trial participants are followed upwhen they attend for
planned clinic appointments. Data on scheduled clinic
appointment attendance, prescription refill collection, and
drug availability are extracted from routinely collected
service-delivery data. At the six-month visit participants
have their blood pressure measured and their contact
details updated if necessary. At the final twelve month
follow-up, anthropometry is repeated and blood pressure
measured, a follow-up questionnaire is administered by
a research assistant and clinical records are reviewed to
capture intervening clinical events and changes in medical
management. Participants who miss their scheduled visit
at 12 months are actively traced by community-based
research staff; if cause for non-attendance is hospital
admission or death, then hospital records or death certifi-
cate data are obtained.Sample size calculations
The trial is powered on the primary outcome measure and
based on a comparison of mean blood pressures between
the usual care group and each of the intervention groups
at 12 months.
A decrease in systolic blood pressure of 5 mm Hg is
associated with clinically important reduction in the
relative risk of stroke and coronary heart disease events.
[4] Based on a study population similar to that expected
for the StAR trial population we used the standard de-
viation (SD) of systolic blood pressure (22.0 mm Hg) to
calculate the required sample size. [9]
With a proposed sample size of at least 1215 participants
(no fewer than 405 for each group) and a 1:1:1 allocation
ratio, the trial will have power of 90% with an alpha of 0.05
(two-sided), to detect an absolute mean difference of 5 mm
Hg in the change in systolic blood pressure at 12 month
from baseline, allowing for up to 20% loss to follow up.
Randomisation
Following receipt of a “Welcome” SMS text-message con-
firming trial registration on the system, participants are
randomised using a secure, remote, web-based computer
schedule within one week of recruitment. A minimisation
procedure, overseen by an independent statistician, is used
to dynamically adjust randomisation probabilities mini-
mising chance differences in gender (male, female), age
(<55 years, ≥ 55 years), baseline systolic blood pressure
(<140 mmHg, ≥ 140 mmHg), years with hypertension
(< 10 years, ≥ 10 years), and previous clinic attendance
(regular, irregular, unknown) between the groups. Research
staff and clinic staff remain blind to the allocated treat-
ment group.
Data collection and management
We used software platforms that are non-proprietary,
open-source, stable and widely available to deliver the
mobile-phone based intervention at scale in a low-resource
setting. We selected software that was easily customisable
and suitable for use by non-technical field staff. Patient
data is collected by fieldworkers using Internet-enabled
mobile phones (HTCWildfire S, HTC Corporation, Taiwan,
Android OS 2.3.5) and tablet computers (Motorola Xoom,
Motorola Corporation, Illinois, Android OS 4.0.4). Data
entry is through on-screen case report forms developed
using the open-source mobile-device application Sana
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is held in OpenMRS version 1.6.1 (OpenMRS, Limited,
Michigan). OpenMRS is an open-source client–server
software platform initially designed as an electronic med-
ical record and health system management platform for
low-resource settings. The database uses a “concept
dictionary” which stores the terms describing each data
variable. It is accessible through a web-based interface
and the platform allows the development, upload and
installation of custom-coded modules into the main frame-
work enabling seamless interactivity with Sana Mobile.
Participant blood pressure readings are transferred directly
from the sphygmomanometer to the tablet computer using
a Bluetooth™ protocol. Data are then securely transferred
to a dedicated mobile dispatch server (MDS) using SSL
transport layer encryption (data are uploaded incre-
mentally to handle intermittent data connectivity). The
MDS then compiles and uploads all the information to an
individual patient electronic medical record in OpenMRS.
Data collected using Sana Mobile are error-checked
using range and logic checks built into Sana at time of
collection. All other data uploaded directly to the data-
base, such as patient appointment attendance, are error-
checked by the OpenMRS software before integration
on the server. These include data format and range
checks, appointment date checks and alignment between
uploaded and existing data. The database is regularly
backed up and password-protected, with differing levels
of access for different research staff.
Statistical methods
Analysis of primary and secondary outcomes
The primary statistical analysis will be carried out on
an intention-to-treat (ITT) basis. We will endeavour to
obtain full follow-up data on every participant to allow
a full ITT analysis. The results from the trial will be re-
ported as comparative summary statistics (difference in
response rate or means) with 95% confidence intervals.
All statistical tests will use a 5% two-sided significance
level. The trial results will be reported in accordance
with the CONSORT (Consolidated Standards of Reporting
Trials) 2010 statements. A full detailed analysis plan
(including plans for subgroup analysis and sensitivity
analysis) will be prepared and finalised before unblind-
ing of the data.
We will analyse the primary outcome (change in systolic
blood pressure at 12 months from baseline) using a
mixed-effects model on data collected at 6 and 12
months. An interaction between time and randomised
group will be fitted to allow estimation of treatment
effects (i.e. informational versus usual care, and inter-
active versus usual care) at each time point. The model
will adjust for baseline systolic blood pressure and
minimisation factors.The secondary outcome measure of adherence will be
dichotomised with a threshold of 80% (of days covered)
to determine the proportion of participants judged ad-
herent to medication. We will use chi-squared tests to
examine differences between allocated groups.
Sub-group analyses
We will carry out sub-group analyses of the primary out-
come, systolic blood pressure and the main secondary
outcome, adherence over last three months, by age
(<50 years, ≥50 years), sex (male, female), number of years
with hypertension (<1, 1–5, >5), baseline blood pressure
(>140, ≤140 mmHg), presence of one or more co-morbid
conditions, and self-reported adherence at baseline.
Missing data will be reported with reasons given where
available and the missing data pattern explored. We will
explore the mechanism of missing data, though the mixed-
effects model does implicitly account for data missing
at random.
Reporting of adverse events for this trial
Reporting of serious adverse events will be limited to
events not already listed as primary or secondary out-
comes, but which might reasonably occur as a conse-
quence of the trial. Additionally we will record adverse
events that might be reasonably related to SMS text-
messaging including hand or finger pain, or involvement
in an accident as a result of sending or receiving a text.
Ethical approval
The Human Research Ethics committees of the University
of Cape Town, the University of Oxford, and the Metro
District Health Services, Western Cape have reviewed
and approved the protocol (HREC UCT 418/211, HREC
OXTREC 03–12). Trial procedures are compliant with the
Declaration of Helsinki and the trial is registered with the
South African National Clinical Trials Register (SANCTR
DOH-27-1212-386) and ClinicalTrials.gov (NCT02019823).
Consent
Eligible, willing participants complete a written consent
form during the initial trial visit. Any participant who has
given consent but loses capacity to consent during the trial
will be withdrawn. Identifiable data already collected with
consent will be retained and used in the analysis.
Publication and dissemination of results
The results of the trial will be published in a peer-
reviewed journal and will be available on PubMed Central
within six months of publication. Dissemination of results
to patients will take place via community meetings, patient
organisations, and the local media. Trial data will be made
available on a public access database.
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This protocol presents the design of a randomised con-
trolled trial testing the efficacy of a text-messaging inter-
vention to support patients in their treatment adherence
and improve blood pressure control. This is the first
controlled trial testing the efficacy of text messaging in a
large population for hypertension, at low cost and in a
low-resource setting. The technology support for this
trial is innovative, based on open-source software, and
not only supports an interactive messaging system using
standard and widely available SMS messaging, but also
integrates clinical care and trial management.
In addition to testing the efficacy of the intervention,
this study will provide information to further develop
clinical care in low-resource settings and maximise the
usefulness of new technology at low cost. It will provide
an evaluation of the feasibility and acceptability of inte-
grating different aspects of clinical care through a deliv-
ery platform which uses the patient’s mobile phone as an
identifier and means of direct contact. The setting pro-
vides a particular challenge, set in a large peri-urban
public sector clinic with a high patient load, typical of
urban centres in Africa and the global south. We are
recruiting participants from a clinic facility that are likely
to be broadly representative of those receiving care for
hypertension at primary care level.
The trial has been designed to address the limitations
of previous studies of SMS text-messages to support
treatment adherence for chronic diseases; [30] the inter-
vention was developed using a formal process to synthe-
sise existing evidence, the opinion of clinical staff, and
patients with chronic diseases, and iteratively tested in
pilot work. There is a large bank of possible messages,
and the delivery system (including interactive bi-direc-
tional SMS text-messaging) is automated. The duration of
the intervention and the length of follow-up will allow us
to explore effects of the intervention on adherence and
persistence with treatment, and to assess whether ha-
bituation to the intervention might moderate the effect.
The outcomes include measurement of adherence, as a
key explanatory variable associated with improved car-
diovascular outcomes, and blood pressure as a clinically
relevant outcome.
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